unknown
Stage
About
FEMSelect develops EnPlace, a same-day, minimally invasive medical device and procedure for treating pelvic organ prolapse. The EnPlace approach is FDA-cleared, was tested in human trials, and is intended to provide pelvic support with typically no overnight hospital stay.
Explore FEMSelect's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.